Editas Medicine (EDIT)
Develops an in vivo CRISPR candidate for lowering LDL cholesterol.
$2.98
vs last close+0.05 (+1.88%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 78.25% | 120.17M shares | |
|---|---|---|---|
| 225 holders · as of Jun 30, 2026 | |||
| Insiders | 0.37% | 564.8K shares | |
| 5 holders · as of Sep 4, 2026 | |||
| Other | 21.38% | 32.84M shares | |
| remainder | |||
153.58M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
13F, as of Jun 30, 2026
225 holders · 120.17M shares · 37 new positions · 113 increased · 41 reduced · 28 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| TCG Crossover Management, LLC | 11.11M | 7.23% | +11.11Mnew | Aug 14, 2026 |
| BlackRock, Inc. | 10.59M | 6.90% | +1.33M | Aug 7, 2026 |
| Ra Capital Management, L.P. | 8.89M | 5.79% | +8.89Mnew | Aug 14, 2026 |
| Commodore Capital LP | 8.89M | 5.79% | +8.89Mnew | Aug 14, 2026 |
| Adar1 Capital Management, LLC | 8.89M | 5.79% | +8.89Mnew | Aug 14, 2026 |
| Vanguard Capital Management LLC | 6.14M | 4.00% | +1.94M | Aug 13, 2026 |
| Paradigm Biocapital Advisors LP | 5.59M | 3.64% | +5.59Mnew | Aug 14, 2026 |
| Opaleye Management Inc. | 3.86M | 2.51% | +1.93M | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Commodore Capital LP | 9.90% | 16.05M | 13G | Jun 2, 2026 |
| BlackRock, Inc. | 7.90% | 6.54M | 13G | Apr 17, 2025 |
| ADAR1 Capital Management, LLC | 5.80% | 8.89M | 13G | Aug 14, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Sep 3, 2026 | Amy Parisonofficer: SVP, Chief Financial Officer | Sale | 453 | $3.04 | 13,839 |
| Sep 3, 2026 | Linda Burklyofficer: EVP, CHIEF SCIENTIFIC OFFICER | Sale | 709 | $3.04 | 61,660 |
| Sep 3, 2026 | Gilmore Neil O'Neilldirector, officer: CEO | Sale | 5,124 | $3.04 | 243,189 |
| Aug 3, 2026 | Amy Parisonofficer: SVP, Chief Financial Officer | Sale | 678 | $2.58 | 14,292 |
| Jul 28, 2026 | Linda Burklyofficer: EVP, CHIEF SCIENTIFIC OFFICER | Sale | 4,928 | $2.67 | 62,369 |
| Jun 3, 2026 | Linda Burklyofficer: EVP, CHIEF SCIENTIFIC OFFICER | Sale | 731 | $2.70 | 67,297 |
| Jun 3, 2026 | Gilmore Neil O'Neilldirector, officer: CEO | Sale | 15,380 | $2.70 | 248,313 |
| Jun 3, 2026 | Amy Parisonofficer: SVP, Chief Financial Officer | Sale | 464 | $2.70 | 14,970 |
| Mar 3, 2026 | Linda Burklyofficer: EVP, CHIEF SCIENTIFIC OFFICER | Sale | 749 | $2.02 | 68,028 |
| Mar 3, 2026 | Amy Parisonofficer: SVP, Chief Financial Officer | Sale | 474 | $2.02 | 15,434 |
House and Senate disclosures
Not reported.